Early osteosclerotic changes predict chemotherapy response in non-small-cell lung cancer patients with bone metastases
- 94 Downloads
To explore the relationship between osteosclerotic changes and chemotherapy response in non-small-cell lung cancer (NSCLC) patients with bone metastases (BM).
Fifty-two NSCLC patients with BM were enrolled from 1 January 2010–31 June 2015 and divided into two groups based on their CT features: an osteosclerotic change (OC) group and a no-osteosclerotic change (NOC) group. The disease control rate (DCR) was evaluated, and progression-free survival (PFS) was analysed using Kaplan-Meier curves. Univariate and multivariate Cox regression analyses were performed to analyse the factors that could affect PFS.
Osteosclerotic changes were observed in 35/52 patients. The median interval when osteosclerotic changes occurred was 2 months (range 1–3 months) after chemotherapy. The OC group had a significantly higher 3-month DCR than the NOC group (p < 0.001). The OC group had a higher 1-year PFS rate than the NOC group (1-year PFS: 74.9% vs. 30.2%, p < 0.001). Univariate Cox regression analysis indicated that pathological subtype (HR = 4.419; 95% CI = 1.635–11.941, p = 0.003) and osteosclerotic changes (HR = 0.199; 95% CI = 0.083–0.477, p < 0.001) were significant predictors of PFS.
Early osteosclerotic changes predict chemotherapy response in NSCLC patients with BM.
• Osteosclerotic changes were prevalent CT features after chemotherapy in NSCLC patients.
• Osteosclerotic changes were positively related to increased 3-month DCR.
• Osteosclerotic changes were positively related to increased 1-year PFS rate.
KeywordsOsteosclerotic changes Non-small-cell lung cancer Bone metastases Computed tomography Progression-free survival
Disease control rate
Without osteosclerotic changes
Non-small-cell lung cancer
We thank the native English-speaking scientists of American Journal Experts for editing our manuscript.
The authors state that this work has not received any funding.
Compliance with ethical standards
The scientific guarantor of this publication is Rong Zhang, Sun Yat-Sen University Cancer Center
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Written informed consent was not required for this study because this was a retrospective study
Institutional Review Board approval was obtained.
• performed at one institution
- 8.Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2012) Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 7:1361–1368Google Scholar
- 9.Kouloulias EV, Kouvaris RJ, Antypas C et al (2003) An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Monitoring of recalcification using image-processing techniques. Strahlenther Onkol 179:471–479CrossRefPubMedGoogle Scholar
- 25.Zheng H, Li W, Kang Y (2017) Tumor-Stroma Interactions in Bone Metastasis: Molecular Mechanisms and Therapeutic Implications. Cold Spring Harb Symp Quant Biol 81:151–161Google Scholar
- 26.Chang CY, Simeone FJ, Torriani M, Bredella MA (2017) Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy. Skeletal Radiol. https://doi.org/10.1007/s00256-017-2706-6